Core B: Analytics for Mucolytics Core
核心 B:粘液溶解核心分析
基本信息
- 批准号:10001595
- 负责人:
- 金额:$ 32.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-07 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:Airborne Particulate MatterAnimal ModelAsthmaBasic ScienceBiochemicalBiochemistryBiologicalBiological AssayBiological MarkersBiological ModelsBiophysicsClinicalClinical TreatmentCommunitiesConeCoughingCystic FibrosisDescriptorDevelopmentDiffusionDiseaseDoctor of PhilosophyEpithelialEpitheliumFunctional disorderGelGoalsHydration statusImaging TechniquesImpairmentIndividualInhalationInstitutesInterventionLaboratoriesLasersLungLung diseasesMUC5AC geneMUC5B geneMass Spectrum AnalysisMeasurementMeasuresMedicineMicroscopicMicrospheresMolecularMolecular StructureMolecular WeightMotivationMucin-2 Staining MethodMucinsMucociliary ClearanceMucolyticsMucous body substanceNorth CarolinaObstructive Lung DiseasesOsmotic PressureParticulatePathologicPathologyPediatricsPhysicsPhysiologicalPhysiologyPlant RootsPolymersPrincipal InvestigatorPropertyRadialReducing AgentsRefractometryResearchResearch PersonnelRespiratory SystemRespiratory physiologyRheologySamplingSolidStructureSulfhydryl CompoundsTalentsTechniquesTherapeuticTherapeutic AgentsTherapeutic InterventionTreatment EfficacyUniversitiesViscosityWaterWeightWestern Blottingbiophysical propertiesclinical efficacycohesiondisulfide bonddisulfide bond reductionefficacy testingexperiencehuman subjectlight scatteringmid-career facultymonomermultidisciplinarynovelpathogenprofessorpulmonary functionrespiratoryskillsstable isotopeviscoelasticity
项目摘要
Abstract
The mucus layer lining the respiratory tract acts as the body's first line of defense against inhaled
pathogens and airborne particulate matter. Proper trapping of particulates and clearance from the lung is
therefore critical to maintaining pulmonary function. The goal of the Analytics for Mucolytics Core is to use the
biochemical and biophysical experimental expertise of its investigators to develop biomarkers of the effect of
disease and therapeutic interventions. These biomarkers will be derived from a multidisciplinary, basic
scientific characterization of pulmonary mucus samples collected by the four Projects of this tPPG. The
motivation for the Analytics for Mucolytics Core is rooted in the goals of this tPPG and can be summarize as
such: 1) elucidate the biological basis of muco-obstructive airway diseases, 2) investigate the polymeric,
physical basis of the underlying pathology of these diseases, and 3) test the efficacy of mucolytic and hydration
therapies. The core will be further governed by the hypothesis that muco-obstructive diseases such as
cystic fibrosis and asthma cause pathological alterations to the biochemical composition of
respiratory mucus, resulting in a hyper-concentrated mucus layer. The thickening of airway mucus leads
to altered biophysical properties that impede mucociliary clearance and ultimately cause a decline in lung
function. The therapeutic goal of this tPPG is to develop clinical treatments that restore pathological mucus to
its proper biochemical and biophysical state, and thereby restore its normal physiological function.
The Analytics for Mucolytics Core will draw on the talents of a diverse team of researchers within the
Marsico Lung Institute who have developed and implemented novel, state-of-the-art experimental capabilities
for the characterization of the biochemical and biophysical properties of mucus. Core PI, Dr. Mehmet Kesimer,
is a world-recognized leader of mucin biochemistry and how changes to the biochemical composition of mucus
correlate to changes in pulmonary function. Dr. Ehre and Dr. Livraghi-Butrico add a wealth of experience in
biochemical imaging techniques of mucins and mucus, and relating these measurements to pulmonary
function in animal model systems and human subjects. Dr. Hill and Dr. Button are experts in the biophysical
characterization of the wide range of mucus sample types the Analytics for Mucolytics Core will analyze from
the diverse projects that make up this tPPG. Dr. Hill and Dr. Button are leaders in relating mucus biophysical
properties to physiological changes. Together, this diverse, multidisciplinary team brings a unique, unrivaled
set of skills that the core will employ to develop biomarkers of pulmonary physiology. Further, the proven track
record of the core investigators working in concert with clinicians will insure that the basic science approach of
the core will be tightly focused on developing biomarkers that are the best descriptors of the physiological
effect of disease and assess efficacy of therapeutic compounds to restore normal lung function.
摘要
呼吸道内的粘液层是人体抵御吸入的第一道防线
病原体和空气中的颗粒物。适当捕获微粒并从肺部清除,
因此对维持肺功能至关重要。粘液溶解核心分析的目标是使用
研究人员的生物化学和生物物理实验专业知识,以开发生物标志物的影响,
疾病和治疗干预。这些生物标志物将来自多学科的,基本的
本tPPG的四个项目采集的肺粘液样本的科学表征。的
粘液溶解分析核心的动机植根于本tPPG的目标,可总结为
例如:1)阐明粘膜阻塞性气道疾病的生物学基础,2)研究聚合物,
这些疾病的潜在病理学的物理基础,以及3)测试粘液溶解和水化的功效
治疗核心将进一步受到以下假设的支配:粘液阻塞性疾病,例如
囊性纤维化和哮喘引起的病理改变的生化组成,
呼吸道粘液,导致高度浓缩的粘液层。气道粘液增厚导致
改变的生物物理特性,阻碍粘膜纤毛清除,并最终导致肺功能下降,
功能该tPPG的治疗目标是开发临床治疗,
恢复其正常的生物化学和生物物理状态,从而恢复其正常的生理功能。
Mucolytics核心分析将利用该领域内多元化研究团队的人才,
Marsico Lung研究所开发并实施了新颖的,最先进的实验能力
用于表征粘液的生物化学和生物物理性质。核心PI,Mehmet Kesimer博士,
是世界公认的粘蛋白生物化学的领导者,
与肺功能的变化有关。Ehre博士和Livraghi-Butrico博士在以下方面积累了丰富的经验:
粘蛋白和粘液的生化成像技术,并将这些测量与肺
在动物模型系统和人类受试者中发挥作用。希尔博士和巴顿博士是生物物理学方面的专家
粘液溶解分析核心将分析的各种粘液样本类型的表征
组成这个tPPG的各种项目。希尔博士和巴顿博士是将粘液生物物理学
属性到生理变化。这支多元化、多学科的团队共同带来了一个独特的、无与伦比的
核心将采用一套技能来开发肺生理学的生物标志物。此外,经过验证的轨道
核心研究人员与临床医生合作的记录将确保基础科学方法,
核心将紧紧集中在开发生物标志物上,这些生物标志物是生理学的最佳描述符,
并评估治疗性化合物恢复正常肺功能功效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mehmet Kesimer其他文献
Mehmet Kesimer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mehmet Kesimer', 18)}}的其他基金
The effect of Inhaled Nicotine on Pulmonary Surfaces
吸入尼古丁对肺表面的影响
- 批准号:
10083514 - 财政年份:2020
- 资助金额:
$ 32.19万 - 项目类别:
The effect of Inhaled Nicotine on Pulmonary Surfaces
吸入尼古丁对肺表面的影响
- 批准号:
10089471 - 财政年份:2017
- 资助金额:
$ 32.19万 - 项目类别:
The effect of Inhaled Nicotine on Pulmonary Surfaces
吸入尼古丁对肺表面的影响
- 批准号:
9234295 - 财政年份:2017
- 资助金额:
$ 32.19万 - 项目类别:
Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
COPD 中的气道粘液/粘蛋白组成和蛋白质组:SPIROMICS 辅助研究
- 批准号:
8521361 - 财政年份:2011
- 资助金额:
$ 32.19万 - 项目类别:
Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
COPD 中的气道粘液/粘蛋白组成和蛋白质组:SPIROMICS 辅助研究
- 批准号:
8215467 - 财政年份:2011
- 资助金额:
$ 32.19万 - 项目类别:
Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
COPD 中的气道粘液/粘蛋白组成和蛋白质组:SPIROMICS 辅助研究
- 批准号:
8323313 - 财政年份:2011
- 资助金额:
$ 32.19万 - 项目类别:
Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
COPD 中的气道粘液/粘蛋白组成和蛋白质组:SPIROMICS 辅助研究
- 批准号:
8688051 - 财政年份:2011
- 资助金额:
$ 32.19万 - 项目类别:
The role of mucin-protein interactions in the innate defense of the lung
粘蛋白-蛋白质相互作用在肺先天防御中的作用
- 批准号:
8656401 - 财政年份:2010
- 资助金额:
$ 32.19万 - 项目类别:
The role of mucin-protein interactions in the innate defense of the lung
粘蛋白-蛋白质相互作用在肺先天防御中的作用
- 批准号:
8116579 - 财政年份:2010
- 资助金额:
$ 32.19万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists